Babayan Anna, Alawi Malik, Gormley Michael, Müller Volkmar, Wikman Harriet, McMullin Ryan P, Smirnov Denis A, Li Weimin, Geffken Maria, Pantel Klaus, Joosse Simon A
Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Bioinformatics Core, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Oncotarget. 2016 Jul 19;8(34):56066-56080. doi: 10.18632/oncotarget.10701. eCollection 2017 Aug 22.
Whole genome amplification (WGA) is required for single cell genotyping. Effectiveness of currently available WGA technologies in combination with next generation sequencing (NGS) and material preservation is still elusive.
In respect to the accuracy of SNP/mutation, indel, and copy number aberrations (CNA) calling, the HiSeq2000 platform outperformed IonProton in all aspects. Furthermore, more accurate SNP/mutation and indel calling was demonstrated using single tumor cells obtained from EDTA-collected blood in respect to CellSave-preserved blood, whereas CNA analysis in our study was not detectably affected by fixation. Although MDA-based WGA yielded the highest DNA amount, DNA quality was not adequate for downstream analysis. PCR-based WGA demonstrates superiority over MDA-PCR combining technique for SNP and indel analysis in single cells. However, SNP calling performance of MDA-PCR WGA improves with increasing amount of input DNA, whereas CNA analysis does not. The performance of PCR-based WGA did not significantly improve with increase of input material. CNA profiles of single cells, amplified with MDA-PCR technique and sequenced on both HiSeq2000 and IonProton platforms, resembled unamplified DNA the most.
We analyzed the performance of PCR-based, multiple-displacement amplification (MDA)-based, and MDA-PCR combining WGA techniques (WGA kits Ampli1, REPLI-g, and PicoPlex, respectively) on single and pooled tumor cells obtained from EDTA- and CellSave-preserved blood and archival material. Amplified DNA underwent exome-Seq with the Illumina HiSeq2000 and ThermoFisher IonProton platforms.
We demonstrate the feasibility of single cell genotyping of differently preserved material, nevertheless, WGA and NGS approaches have to be chosen carefully depending on the study aims.
单细胞基因分型需要进行全基因组扩增(WGA)。目前可用的WGA技术与下一代测序(NGS)及样本保存相结合的有效性仍不明确。
在单核苷酸多态性/突变(SNP/mutation)、插入缺失(indel)及拷贝数变异(CNA)检测的准确性方面,HiSeq2000平台在各方面均优于IonProton平台。此外,与保存于CellSave中的血液相比,使用从EDTA抗凝血液中获取的单个肿瘤细胞能实现更准确的SNP/mutation和indel检测,而在本研究中,固定对CNA分析没有明显影响。尽管基于多重置换扩增(MDA)的WGA产生的DNA量最高,但其质量不足以用于下游分析。在单细胞的SNP和indel分析中,基于PCR的WGA技术优于MDA-PCR联合技术。然而,MDA-PCR WGA的SNP检测性能随输入DNA量的增加而提高,而CNA分析则不然。基于PCR的WGA性能不会随输入样本量的增加而显著改善。使用MDA-PCR技术扩增并在HiSeq2000和IonProton平台上测序的单细胞CNA图谱与未扩增的DNA最为相似。
我们分析了基于PCR、基于多重置换扩增(MDA)以及MDA-PCR联合的WGA技术(分别为WGA试剂盒Ampli1、REPLI-g和PicoPlex)对从EDTA抗凝血液、保存于CellSave中的血液及存档样本中获取的单个及混合肿瘤细胞的性能。扩增后的DNA在Illumina HiSeq2000和ThermoFisher IonProton平台上进行外显子组测序。
我们证明了对不同保存样本进行单细胞基因分型的可行性,不过,必须根据研究目的谨慎选择WGA和NGS方法。